Blog
RSS FeedPosted by Michael Wonder on 26 Aug 2021
PHARMAC seeks feedback on a biosimilar brand of adalimumab being considered for funding
26 August 2021 - PHARMAC is considering awarding Principal Supply to a biosimilar brand of adalimumab (Amgevita) from 1 February ...
Posted by Michael Wonder on 05 Aug 2021
Treasury wanted Labour to break all health election promises bar one
5 August 2021 - Treasury told the Government to kick its election promises like funding for PHARMAC, cochlear implants, and ...
Posted by Michael Wonder on 05 Aug 2021
G1 Therapeutics granted new technology add-on payment for Cosela (trilaciclib) by CMS
4 August 2021 - G1 Therapeutics today announced that CMS has granted a new technology add-on payment for Cosela (trilaciclib ...
Posted by Michael Wonder on 04 Aug 2021
Cerus Corporation announces CMS has granted new technology add-on payment for INTERCEPT fibrinogen complex
3 August 2021 - New technology add-on payment provides incremental reimbursement under CMS’ Inpatient Prospective Payment System for INTERCEPT Fibrinogen Complex. ...
Posted by Michael Wonder on 27 Jul 2021
$3.3 million to support Australians living with a rare disease
27 July 2021 - The Australian Government is providing $3.3 million to support the approximate two million Australians living with a ...
Posted by Michael Wonder on 22 Jul 2021
NHS England unveils new Innovative Medicine Fund
21 July 2021 - NHS England has unveiled its new Innovative Medicines Fund, to ensure patients have early access to ...
Posted by Michael Wonder on 21 Jul 2021
Americans’ medical debts are bigger than was known, totalling $140 billion
20 July 2021 - A new study finds that health care has become the country’s largest source of debt in collections. ...
Posted by Michael Wonder on 19 Jul 2021
Will CMS find aducanumab reasonable and necessary for Alzheimer disease after FDA approval?
19 July 2021 - The recent US FDA approval of aducanumab for the treatment of Alzheimer disease triggered both praise and ...
Posted by Michael Wonder on 14 Jul 2021
PM speaks about COVID-19, Fiji and PHARMAC funding
14 July 2021 - Prime Minister Jacinda Ardern spoke to media after a speech at the New Zealand Institute of International ...
Posted by Michael Wonder on 01 Jul 2021
Guaranteeing Medicare
1 July 2021 - The Australian Government is investing record funding in Medicare, providing more support to Australians as we face ...
Posted by Michael Wonder on 30 Jun 2021
Will Biogen’s new Alzheimer’s drug’s burden on Medicare be big, huge, or catastrophic?
28 June 2021 - The FDA’s decision to grant wide-ranging approval to the controversial, pricey new Alzheimer’s drug Aduhelm will ...
Posted by Michael Wonder on 03 Jun 2021
'We're not just all about the money' — PHARMAC defends why it still won't fund drug for rare children's disorder
3 June 2021 - Under-fire PHARMAC is defending the way it funds New Zealand's drugs, with the agency's director of operations, ...
Posted by Michael Wonder on 02 Jun 2021
The economics of alternative payment models for pharmaceuticals
1 June 2021 - Pharmaceuticals are priced uniformly by convention, but vary in their degree of effectiveness for different disease indications. ...
Posted by Michael Wonder on 30 May 2021
PHARMAC funding will result in health poverty: advocate
30 May 2021 - A Dunedin patient rights campaigner is vowing to fight on in the wake of the Government’s ...
Posted by Michael Wonder on 25 May 2021
Dupixent (dupilumab) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate to severe atopic dermatitis
25 May 2021 - Dupixent is the only biologic medicine approved by Health Canada to treat moderate to severe atopic dermatitis. ...